BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37217509)

  • 41. Receptor mutation is not a common mechanism of naturally occurring glucocorticoid resistance in leukaemia cell lines.
    Beesley AH; Weller RE; Senanayake S; Welch M; Kees UR
    Leuk Res; 2009 Feb; 33(2):321-5. PubMed ID: 18789525
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PON2 blockade overcomes dexamethasone resistance in acute lymphoblastic leukemia.
    Hui PY; Chen YH; Qin J; Jiang XH
    Hematology; 2022 Dec; 27(1):32-42. PubMed ID: 34957927
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting the thioredoxin system as a novel strategy against B-cell acute lymphoblastic leukemia.
    Fidyt K; Pastorczak A; Goral A; Szczygiel K; Fendler W; Muchowicz A; Bartlomiejczyk MA; Madzio J; Cyran J; Graczyk-Jarzynka A; Jansen E; Patkowska E; Lech-Maranda E; Pal D; Blair H; Burdzinska A; Pedzisz P; Glodkowska-Mrowka E; Demkow U; Gawle-Krawczyk K; Matysiak M; Winiarska M; Juszczynski P; Mlynarski W; Heidenreich O; Golab J; Firczuk M
    Mol Oncol; 2019 May; 13(5):1180-1195. PubMed ID: 30861284
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.
    Uemura S; Nishimura N; Hasegawa D; Shono A; Sakaguchi K; Matsumoto H; Nakamachi Y; Saegusa J; Yokoi T; Tahara T; Tamura A; Yamamoto N; Saito A; Kozaki A; Kishimoto K; Ishida T; Nino N; Takafuji S; Mori T; Iijima K; Kosaka Y
    Int J Hematol; 2018 May; 107(5):604-609. PubMed ID: 29177615
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glucocorticoid receptor heterozygosity combined with lack of receptor auto-induction causes glucocorticoid resistance in Jurkat acute lymphoblastic leukemia cells.
    Riml S; Schmidt S; Ausserlechner MJ; Geley S; Kofler R
    Cell Death Differ; 2004 Jul; 11 Suppl 1():S65-72. PubMed ID: 15017388
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Integrated bioinformatics analysis of the crucial candidate genes and pathways associated with glucocorticoid resistance in acute lymphoblastic leukemia.
    Chen Y; Jiang P; Wen J; Wu Z; Li J; Chen Y; Wang L; Gan D; Chen Y; Yang T; Lin M; Hu J
    Cancer Med; 2020 Apr; 9(8):2918-2929. PubMed ID: 32096603
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway.
    Tsapis M; Lieb M; Manzo F; Shankaranarayanan P; Herbrecht R; Lutz P; Gronemeyer H
    Int J Biochem Cell Biol; 2007; 39(7-8):1500-9. PubMed ID: 17499001
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
    Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
    Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glucocorticoid receptor alpha, beta and gamma expression vs in vitro glucocorticod resistance in childhood leukemia.
    Haarman EG; Kaspers GJ; Pieters R; Rottier MM; Veerman AJ
    Leukemia; 2004 Mar; 18(3):530-7. PubMed ID: 14724649
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.
    Harr MW; Caimi PF; McColl KS; Zhong F; Patel SN; Barr PM; Distelhorst CW
    Cell Death Differ; 2010 Sep; 17(9):1381-91. PubMed ID: 20300113
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glycoproteome remodeling in MLL-rearranged B-cell precursor acute lymphoblastic leukemia.
    Oliveira T; Zhang M; Joo EJ; Abdel-Azim H; Chen CW; Yang L; Chou CH; Qin X; Chen J; Alagesan K; Almeida A; Jacob F; Packer NH; von Itzstein M; Heisterkamp N; Kolarich D
    Theranostics; 2021; 11(19):9519-9537. PubMed ID: 34646384
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of recombinant cell-permeable small peptides to modulate glucocorticoid sensitivity of acute lymphoblastic leukemia cells.
    Geng CD; Vedeckis WV
    Biochemistry; 2010 Oct; 49(41):8892-901. PubMed ID: 20831260
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effects of microRNAs on glucocorticoid responsiveness.
    Wang H; Gou X; Jiang T; Ouyang J
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1005-1011. PubMed ID: 28286901
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quantitative analysis and modeling of glucocorticoid-controlled gene expression.
    Chen DW; Lynch JT; Demonacos C; Krstic-Demonacos M; Schwartz JM
    Pharmacogenomics; 2010 Nov; 11(11):1545-60. PubMed ID: 21121775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Wnt signaling pathway regulates Nalm-16 b-cell precursor acute lymphoblastic leukemic cell line survival and etoposide resistance.
    Thiago LS; Costa ES; Lopes DV; Otazu IB; Nowill AE; Mendes FA; Portilho DM; Abreu JG; Mermelstein CS; Orfao A; Rossi MI; Borojevic R
    Biomed Pharmacother; 2010 Jan; 64(1):63-72. PubMed ID: 19864107
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overcoming Microenvironment-Mediated Chemoprotection through Stromal Galectin-3 Inhibition in Acute Lymphoblastic Leukemia.
    Tarighat SS; Fei F; Joo EJ; Abdel-Azim H; Yang L; Geng H; Bum-Erdene K; Grice ID; von Itzstein M; Blanchard H; Heisterkamp N
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830047
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epigenomic profiling of glucocorticoid responses identifies cis-regulatory disruptions impacting steroid resistance in childhood acute lymphoblastic leukemia.
    Bergeron BP; Diedrich JD; Zhang Y; Barnett KR; Dong Q; Ferguson DC; Autry RJ; Yang W; Hansen BS; Smith C; Crews KR; Fan Y; Pui CH; Pruett-Miller SM; Relling MV; Yang JJ; Li C; Evans WE; Savic D
    Leukemia; 2022 Oct; 36(10):2374-2383. PubMed ID: 36028659
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.
    Meyer LK; Delgado-Martin C; Maude SL; Shannon KM; Teachey DT; Hermiston ML
    PLoS One; 2019; 14(7):e0220026. PubMed ID: 31318944
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changes of glucocorticoid receptor isoforms expression in acute lymphoblastic leukemia correlate with glucocorticoid resistance.
    Sun X; Fang M; Guan Y; Si Y; Ma L; Wang Y; Jia Z
    Pharmazie; 2015 May; 70(5):316-21. PubMed ID: 26062300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.